Rifaximin for Preventing Progression and Complications in Patients With Decompensated Liver Cirrhosis
Condition(s):Decompensated CirrhosisLast Updated:August 8, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Decompensated CirrhosisLast Updated:August 8, 2023Recruiting
Condition(s):Irritable Bowel Syndrome With DiarrheaLast Updated:March 28, 2023Completed
Condition(s):CirrhosisLast Updated:February 28, 2014Unknown status
Condition(s):DysbiosisLast Updated:March 22, 2022Unknown status
Condition(s):Irritable Bowel SyndromeLast Updated:December 30, 2021Unknown status
Condition(s):Metastatic Lung CancerLast Updated:October 2, 2023Recruiting
Condition(s):Parkinson’s Disease AggravatedLast Updated:January 29, 2021Completed
Condition(s):HIVLast Updated:February 26, 2020Completed
Condition(s):Liver Cirrhosis; Hepatic EncephalopathyLast Updated:February 23, 2016Completed
Condition(s):ObesityLast Updated:December 7, 2023Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.